Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia
Back to article page
Clinical Experience|Updated:2023-08-29
|
Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia
Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia
中国结合医学杂志(英文版)2023年29卷第9期 页码:832-837
Affiliations:
1.Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
2.Graduate School, China Academy of Chinese Medical Sciences, Beijing (100700), China
Author bio:
Prof. HU Xiao-mei, E-mail: huxiaomei_2@163.com
Funds:
the National Natural Science Foundation of China(81673821;81774142);the Special Research Foundation of Central Level Public Scientific Research Institutes(ZZ10-016)
Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia[J]. 中国结合医学杂志(英文版), 2023,29(9):832-837.
WU Yu-he, XIAO Hai-yan, QUAN Ri-cheng, et al. Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia[J]. Chinese Journal of Integrative Medicine, 2023,29(9):832-837.
Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia[J]. 中国结合医学杂志(英文版), 2023,29(9):832-837. DOI: 10.1007/s11655-023-3603-6.
WU Yu-he, XIAO Hai-yan, QUAN Ri-cheng, et al. Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia[J]. Chinese Journal of Integrative Medicine, 2023,29(9):832-837. DOI: 10.1007/s11655-023-3603-6.
Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia
摘要
Abstract
Objective:
2
To compare the clinical effect of arsenic-containing Qinghuang Powder (QHP) and low-intensity chemotherapy (LIC) in treatment of elderly acute myeloid leukemia (eAML) patients.
Methods:
2
Clinical data of 80 eAML patients treated at Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 2015 to December 2020 were retrospectively analyzed. The treatment scheme was designed by real world study according to patients' preference
and patients were divided into a QHP group (35 cases) and a LIC group (45 cases). The median overall survival (mOS)
1-
2-
and 3-year OS rates
and incidence of adverse events were compared between the two groups.
Results:
2
The mOS of 80 patients was 11 months
and the 1-
2-
and 3-year OS rates were 45.51%
17.96%
and 11.05%
respectively. The QHP and LIC groups demonstrated no significant difference in mOS (12 months
vs
. 10 months)
1- (48.57%
vs
. 39.65%)
2- (11.43%
vs
. 20.04%)
and 3-year OS rates (5.71%
vs
. 13.27%
all
P
>
0.05). Moreover
the related factors of mOS demonstrated no significant difference in patients with age
>
75 years (11 months
vs
. 8 months)
secondary AML (11 months
vs
. 8 months)
poor genetic prognosis (9 months
vs
. 7 months)
Eastern Cooperative Oncology Group performance status score 3 (10 months
vs
. 7 months) and hematopoietic stem cell transplant comorbidity index 4 (11 months
vs
. 7 months) between the QHP and LIC groups (all
P
>
0.05). However
the incidence of myelosuppression was significantly lower in the QHP group than that in the LIC group (28.57%
vs
. 73.33%
P
<
0.01).
Conclusions:
2
QHP and LIC had similar survival rates in eAML patients
but QHP had a lower myelosuppression incidence. Hence
QHP can be an alternative for eAML patients who do not tolerate LIC.
关键词
Keywords
acute myeloid leukemiaelderlyQinghuang Powderlow-intensity chemotherapyChinese medicine
Arsenic-Containing Qinghuang Powder (青黄散) Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy
Oral Arsenic-Containing Qinghuang Powder:A Potential Drug for Myelodysplastic Syndromes
Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder (青黄散) in Patients with Myelodysplastic Syndrome
Effect of Qinghuang Powder (青黄散) Combined with Bupi Yishen Decoction (补脾益肾方) in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation
Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini
相关作者
暂无数据
相关机构
Graduate School of China Academy of Chinese Medical Sciences
Graduate School of Beijing University of Chinese Medicine
Zhengyuan Clinic of Nantong
National Hematological Medical Center of Traditional Chinese Medicine, Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences
Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine